The global point-of-care diagnostics market is projected to grow from $20.63 billion in 2026 to $31.46 billion by 2031, a compound annual growth rate of 8.8%, according to a ResearchAndMarkets.com report. Demand is being driven by the need for rapid, accurate and decentralized testing across hospitals, laboratories, emergency departments, physician offices, retail clinics, pharmacies and home healthcare settings. Biochemistry holds the largest technology share because of its established use in glucose, blood gas, electrolyte and cholesterol testing, while molecular diagnostics is forecast to expand fastest as rapid PCR platforms are adopted for infectious-disease detection, antimicrobial-resistance testing and outbreak preparedness. Infectious-disease testing products are projected to be the fastest-growing product segment, and clinical laboratories remain the largest end-user segment. North America leads the market, supported by healthcare infrastructure, reimbursement frameworks, regulatory support and adoption of near-patient diagnostics in the United States and Canada. The report identifies advances in immunoassays, microfluidics, multiplex testing, biosensors, artificial intelligence-enabled diagnostics and smartphone-integrated testing as important adoption factors, while noting cost, regulation, test accuracy, data security, reimbursement, supply-chain and interoperability challenges.